This page explains how material on Retatrutide-Peptide.info is researched, drafted, reviewed, and corrected. Because the drug we cover is still under investigation, the evidence keeps shifting, and much of what circulates online amounts to personal stories or marketing material. The standards below are the ones we follow.
Information sources
Facts are drawn from sources, ranked by the following order of preference:
- Peer-reviewed trial publications the primary publications reporting retatrutide clinical trials.
- Trial registries ClinicalTrials.gov entries covering trial design, dosage arms, and status.
- Regulators the FDA regarding approval status, compounding rules, and safety alerts.
- Government health bodies NIH, NIDDK, and other established institutions for background physiology.
Forum posts, vendor pages, influencer videos, and AI summaries are not treated by us as factual sources. Where we cover anecdotal reports, for instance on our reviews pagewe label that material plainly as anecdote and note that it has not been verified.
How we handle discussion of an investigational drug
- Every page states plainly that retatrutide has not been approved by the FDA.
- Trial data are tied to the specific trial they come from, with phase and dose named, and are never framed as typical outcomes.
- We deliberately choose hedged wording such as 'may,' 'in trials,' and 'as reported.' We never promise outcomes.
- We do not publish dosing schedules, administration guidance, or instructions for personal use. Everything we offer is intended solely for laboratory research.
- We do not post before-and-after images, named testimonials, or any visuals that could imply proof of results.
Medical review
Science pages undergo review before publication and are checked again whenever the evidence or regulatory status shifts. A review confirms that the content matches its cited sources, relies on appropriate hedging, and contains nothing that could read as personalized medical advice or directions for human consumption. A review is not an endorsement of any product or vendor, and reviewers play no role in sales.
Reviewed pages show the reviewer's name, credentials, and review date. Reviewers are listed on our authors and reviewers page.
Setup note: reviewer names and dates must belong to the actual clinicians who took part in reviewing the content. A byline may only credit someone who truly reviewed the page.
Review schedule
| Content type | Review cadence | Also triggered by |
|---|---|---|
| Mechanism and pharmacology | Every 6 months | Any new peer-reviewed publication |
| Safety and side effects | Every 6 months | New safety alerts or FDA communications |
| FDA status and news | Every 3 months | Any regulatory or trial milestones |
| Comparisons and market | Every 12 months | Approval or pricing updates concerning a comparator compound |
Independence and advertising
We earn revenue when customers buy research-grade materials from our store, as explained on our about pageWe do not sell guest posts, we do not take payment to endorse particular vendors or labs, and no outside party gets a preview of our content before it goes live.
Corrections
When we get something wrong, we fix it openly and clearly. Substantive changes are noted at the bottom of the page with the date and a short explanation; typos and minor fixes are made silently. To report a mistake, email support@retatrutide-peptide.info with the page URL and, where possible, a source reference.
Use of AI
We use AI tools for drafting support and layout. Nothing goes live until a human editor has reviewed it against the primary references cited above. Machine-generated text is never published on scientific topics without that editorial review.
Research-grade · COA per lot